SCHEMBL4091310

SCHEMBL4091310

CCOC(=O)C(C(=O)Cc1ccccc1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP8 P22894 2/20 0.60
▸ MEN1 O00255 1/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ TSHR P16473 3/20 0.46
▸ PIN1 Q13526 1/20 0.45
▸ SLC6A2 P23975 3/20 0.44
▸ SLC6A3 Q01959 3/20 0.44
▸ SLC6A4 P31645 2/20 0.44
▸ LMNA P02545 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ CNR2 P34972 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL957814 0.85 MMP8 (0.66) MMP8MEN1NPC1KMT2ACA12
SCHEMBL266419 0.84 MMP8 (0.74) MMP8MEN1NPC1KMT2ACA12
SCHEMBL28674585 0.83 MMP8 (0.72) MMP8MEN1NPC1KMT2ACA12
SCHEMBL31069943 0.83 MMP8 (0.72) MMP8MEN1NPC1KMT2ACA12
SCHEMBL3407979 0.82 MMP8 (0.43) MMP8MEN1NPC1KMT2ACA12
SCHEMBL11497870 0.82 MMP8 (0.62) MMP8MEN1NPC1KMT2ACA12
SCHEMBL10608461 0.82 MMP8 (0.62) MMP8MEN1NPC1KMT2ACA12
SCHEMBL13495167 0.81 MMP8 (0.50) MMP8MEN1NPC1KMT2ATSHR
SCHEMBL1275691 0.81 MMP8 (0.70) MMP8MEN1NPC1KMT2ACA12
SCHEMBL5141926 0.81 MMP8 (0.65) MMP8MEN1NPC1KMT2ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962834-B2 Modulators of amyloid beta HOFFMANN-LA ROCHE INC. (US) 2015-02-24 — — US disclosed
EP-2257541-B1 MODULATORS FOR AMYLOID BETA HOFFMANN LA ROCHE (CH) 2013-08-14 — — EP disclosed
US-20130190302-A1 MODULATORS OF AMYLOID BETA HOFFMANN-LA ROCHE INC. (US) 2013-07-25 — — US disclosed
US-20090215759-A1 MODULATORS FOR AMYLOID BETA HOFFMANN-LA ROCHE, INC. 2009-08-27 — — US disclosed
US-4102669-A IN COTTON CULTURE ELI LILLY AND COMPANY (US) 1978-07-25 — — US disclosed
US-4065290-A Herbicidal β-phenyl-4-piperidinones ELI LILLY AND COMPANY (US) 1977-12-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215759-A1 MODULATORS FOR AMYLOID BETA APP, PSEN1, APOB MMP8 3027/4885MEN1 1852/4885NPC1 437/4885
US-20130190302-A1 MODULATORS OF AMYLOID BETA APP, PSEN1, APOB MMP8 3031/4885MEN1 1873/4885NPC1 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback